Tissue decorporation of polonium-210 in rats by DMPA.
Aposhian-HV; Dart-RC; Aposhian-MM; Dawson-BV
Res Commun Chem Pathol Pharmacol 1987 Nov; 58(2):157-171
Male Sprague-Dawley-rats were tested to determine the efficacy of N- (2,3-dimercaptopropyl)phthalamidic-acid (13312782) (DMPA), meso- dimercaptosuccinic-acid (304552) (DMSA) and the sodium salt of 2,3- dimercapto-1-propanesulfonic-acid (4076022) (DMPS) as antidotes and decorporating agents for polonium-210 (20537886) (Po-210). Rats treated intraperitoneally with Po-210 at a dose of 40 microcuries per kilogram had a median survival time of 39 days. Following subcutaneous administration of DMPA, DMSA or DMPS at 0.20 millimoles per kilogram (given 1, 90 and 360 minutes and twice daily 2, 3, 4, 12, 22 and 32 days after Po-210), the mean survival time increased to 106 days. Decorporation studies were carried out in animals treated subcutaneously with 0.4 microcuries Po-210, followed by a series of subcutaneous injections with DMPA, DMSA, DMPS, N-acetyl- cysteine or WR2721 starting one hour after Po-210 administration. Twenty one days after Po-210 treatment the levels of Po-210 in the kidney and spleen of rats treated subsequently with DMPA represented, respectively, only 28 and 25 percent of the amount present in the corresponding tissues of controls. The levels of Po- 210 in the kidneys of animals subsequently treated with DMSA, DMPS, N-acetyl-cysteine or WR2721 were significantly higher than those recorded in the rats treated with DMPA. The authors conclude that DMPA is a consistent decorporating agent for Po-210.
NIOSH-Publication; NIOSH-Grant; Pulmonary-system-disorders; Radioactive-isotopes; Metabolic-study; Detoxifying-agents; Laboratory-animals; In-vivo-studies; Chelates; Kidney-function; Thiols
Molecular and Cellular Biology University of Arizona Biosciences West Bldg Tucson, AZ 85721
13312-78-2; 304-55-2; 4076-02-2; 20537-88-6
Research Communications in Chemical Pathology and Pharmacology
University of Arizona, Tucson, Arizona